Inflammatix

Inflammatix can identify the presence and severity of an infection in only 30 minutes, enabling doctors to quickly diagnose and select the best treatment for patients. Instead of looking for a specific infection cause, Inflammatix reads a patient’s immune system to capture what the human body is fighting. By capturing this unique view, Inflammatix rapidly translates information into actionable results. The company’s core technology was hypothesized during Inflammatix’s Co-founder and CEO Dr. Timothy Sweeney’s time at the Khatri Lab at Stanford University, which focuses on developments in machine learning applied to biomedical research.